0000000000088494

AUTHOR

H. Swars

showing 4 related works from this author

Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).

1991

Despite the improvements in the development of dialyzer membranes with greater hemocompatibility, an activation of the coagulation system occurs when blood comes into contact with exogenous surfaces. The large number of heparin dosage regimens demonstrate the difficulty to adapt general therapeutic guidelines. Low molecular weight heparin (Fragmin®) was administered as a single bolus dose for anticoagulation during 58 acute dialyses. Anti-Xa-activity, the plasma levels of the lysosomal elastase of the polymorphnuclear granulocytes (“PMN-elastase”) and of the thrombin-antithrombin III-complex (TAT) were measured at hourly intervals. Therapeutic anti-Xa-levels did not show evidence of suffici…

Malemedicine.medical_specialtymedicine.drug_classAntithrombin IIILow molecular weight heparinPharmacologyCritical Care and Intensive Care MedicineRenal DialysismedicineHumansPancreatic elastaseAgedbiologyPancreatic Elastasebusiness.industryElastaseAnticoagulantThrombosisHeparinAcute Kidney InjuryHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryCoagulationNeutrophil elastasebiology.proteinFemalebusinessLeukocyte Elastasemedicine.drugPeptide HydrolasesIntensive care medicine
researchProduct

Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting

1992

Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1 + 2 (F 1 + 2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F 1 + 2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyAdministration OralPhenprocoumonmedicineHumansAngioplasty Balloon CoronaryAgedChemotherapyHeparinbusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantAnticoagulantsHematologyGeneral MedicineHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisPeptide FragmentsDipyridamoleHeart Valve ProsthesisAnesthesiaPhenprocoumonFemaleProthrombinStentsPulmonary EmbolismComplicationbusinessmedicine.drugAnnals of Hematology
researchProduct

Determination of Human Granulocyte Elastase by the Immunoactivation Method on the Hitachi® 717 Automated Analyser

1991

This paper describes a fully mechanized homogeneous immunoassay using the immunoactivation method for the rapid and specific determination of human granulocyte elastase (EC 3.4.21.37) in plasma. The method uses anti-elastase antibody fragments from sheep, conjugated to horseradish peroxidase. These enzyme-antibody conjugates bind to the elastase-alpha 1-proteinase inhibitor complex present in plasma. A separate sample blank with non-specific sheep antibody fragments conjugated to horseradish peroxidase corrects for errors introduced by the sample matrix. Measurements were performed with the clinical chemistry analyser Hitachi 717. A single determination can be performed in 10 min, requiring…

Pathologymedicine.medical_specialtyeducationClinical BiochemistryEnzyme-Linked Immunosorbent AssayGranulocyteHorseradish peroxidaseReference ValuesBlood plasmamedicineHumansAutomated analyserAutoanalysisChromatographyPancreatic Elastasebiologymedicine.diagnostic_testBiochemistry (medical)ElastaseGeneral Medicinemedicine.anatomical_structureImmunoassaybiology.proteinLeukocyte ElastaseQuantitative analysis (chemistry)ConjugateClinical Chemistry and Laboratory Medicine
researchProduct

The control of anti-coagulation in acute dialyses with sensitive laboratory parameters.

1992

In seven patients who had to be dialysed between four and 13 times due to acute renal failure, low molecular weight heparin (LMWH) Fragmin was used for anticoagulation. According to dose-finding studies, 80-90 U kg-1 body weight of LMWH as a single bolus were administered initially, producing dose-related levels of 0.3-1.5 anti-factor Xa U ml-1 in plasma. Apart from the anti-Xa activity in the plasma, the thrombin anti-thrombin III complex (TAT complex) and a fibrin degradation product (D-dimer) were measured as parameters of a coagulation activation. A sufficient anti-coagulation during dialysis was supposed to exist at a normal range (5.0 micrograms l-1 or below) of TAT complex. Pathologi…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentClinical BiochemistryAntithrombin IIILow molecular weight heparinPharmacologyFibrin Fibrinogen Degradation ProductsThrombinRenal DialysisD-dimermedicineHumansBlood CoagulationDialysisAgedFibrin degradation productbusiness.industryAnticoagulantExtracorporeal circulationAnticoagulantsGeneral MedicineHeparinAcute Kidney InjuryHeparin Low-Molecular-WeightMiddle AgedSurgerybusinessmedicine.drugFactor Xa InhibitorsPeptide HydrolasesScandinavian journal of clinical and laboratory investigation
researchProduct